Document Detail

Impact of angiotensin II receptor blocker on plasma levels of adiponectin and advanced oxidation protein products in peritoneal dialysis patients.
MedLine Citation:
PMID:  16940715     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Oxidative stress and adipocytokines are reported to contribute to the pathogenesis of atherosclerosis. Though the inhibition of the renin-angiotensin system is known to have beneficial effects on atherosclerosis, the exact mechanisms for this remain to be clarified. The aim of this study was to determine the effects of angiotensin II receptor blockers (ARB) on the oxidative stress and adipocytokines in peritoneal dialysis patients.
METHODS: Candesartan (8 mg/day), an ARB, was administered for 3 months to 8 nondiabetic patients on peritoneal dialysis. Plasma levels of advanced oxidation protein products (AOPP) and adiponectin were measured before and 3 months after candesartan administration, and 3 months after discontinuation.
RESULTS: Plasma AOPP level decreased from 377.5 to 305.6 micromol/l (p < 0.05) following the administration of candesartan and returned to 394.6 micromol/l (p < 0.05) by 3 months after the discontinuation of the drug. Plasma adiponectin level increased from 12.5 to 18.8 microg/ml (p < 0.05) by candesartan and decreased again to 14.4 microg/ml (p < 0.05) after discontinuation. There was a significant inverse relationship between changes in plasma level of adiponectin and AOPP (r = - 0.888, p < 0.01).
CONCLUSION: Candesartan increases plasma adiponectin level in association with the reduction of oxidative stress in peritoneal dialysis patients. Candesartan may be useful in preventing atherosclerosis in peritoneal dialysis patients.
Ryuichi Furuya; Mari Odamaki; Hiromichi Kumagai; Akira Hishida
Related Documents :
7868875 - Angiotensin ii type 1 receptor messenger rna levels in human blood cells of patients wi...
7973905 - Reversible hyperkalemia during antihypertensive therapy in a hypertensive diabetic pati...
2543535 - Kinetics and dynamics of enalapril in patients with liver cirrhosis.
23933865 - Hypothyroidism and acute kidney injury: an unusual association.
23011135 - Thyroid hormone determines the start of the sensitive period of imprinting and primes l...
11750735 - Follicle-stimulating hormone and advanced follicle development in the human.
Publication Detail:
Type:  Journal Article     Date:  2006-08-25
Journal Detail:
Title:  Blood purification     Volume:  24     ISSN:  0253-5068     ISO Abbreviation:  Blood Purif.     Publication Date:  2006  
Date Detail:
Created Date:  2006-12-27     Completed Date:  2007-02-06     Revised Date:  2013-05-28    
Medline Journal Info:
Nlm Unique ID:  8402040     Medline TA:  Blood Purif     Country:  Switzerland    
Other Details:
Languages:  eng     Pagination:  445-50     Citation Subset:  IM    
Renal Division, Department of Internal Medicine, Iwata City Hospital, Iwata, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Adiponectin / blood*
Angiotensin II Type 1 Receptor Blockers / administration & dosage*
Atherosclerosis / blood,  etiology,  prevention & control
Benzimidazoles / administration & dosage*
Blood Proteins / analysis*
Kidney Failure, Chronic / blood*,  complications,  therapy*
Middle Aged
Oxidation-Reduction / drug effects
Oxidative Stress / drug effects*
Peritoneal Dialysis*
Tetrazoles / administration & dosage*
Time Factors
Reg. No./Substance:
0/Adiponectin; 0/Angiotensin II Type 1 Receptor Blockers; 0/Benzimidazoles; 0/Blood Proteins; 0/Tetrazoles; S8Q36MD2XX/candesartan

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  No benefit of hemodiafiltration over hemodialysis in lowering elevated levels of asymmetric dimethyl...
Next Document:  Cardiac vascular calcification and QT interval in ESRD patients: is there a link?